OP White Papers - random
-
Controlling Trace Impurities In Chemically Defined Media
4/10/2023
Discover a novel approach for manufacturing chemically defined media with precision control of trace impurities that utilizes innovative raw material analysis, data analytics, and a proprietary algorithm.
-
Development And Regulation Of Veterinary Monoclonals
2/8/2024
Although veterinary mAbs have achieved commercial success, ongoing discussions and clinical developments surrounding them are expected to outline a clear regulatory pathway in the near future.
-
Pharma Research, Development, & Launches Save Lives — & The Earth
6/1/2023
Understand how a defined framework and way of measuring allows companies to align priorities, short- or long-term goals, and what ESG success looks like.
-
Placing Drug Strategies On A Solid Foundation For Success
4/21/2022
Explore how certain drivers are impacting traditional drug development strategies and relationships with outsourced drug development and manufacturing partners.
-
Quality Implications Of CO2 Sensing In Bioreactor Applications
9/18/2023
Examine the technologies underpinning the current sensors being utilized in dissolved CO2 measurement devices today and determine which sensors are appropriate for your application.
-
Revolutionizing Particle Characterization With Image Analysis And ML
9/27/2023
The biopharmaceutical industry is increasingly employing micro-flow imaging for particle characterization, owing to the superior insights it can afford into product quality and process controls.
-
Collaborating With A CMO To Bring Your Sterile Injectable Product To Market
2/15/2023
Review considerations for collaborating with a fill/finish CMO, including CMO selection, Request for Proposal (RFP) delivery, proposal review, and project award.
-
An Experienced CDMO Can Be A Differentiator In The Rapidly Growing Biologics Market
12/14/2023
Biotech and biopharma developers are increasingly relying on outsourcing partners to meet both clinical and commercial research, development, and production needs. CDMOs that provide end-to-end services, including secure supply chains, can help biologics developers meet accelerated timelines and establish a real competitive advantage in today’s competitive market.
-
Extractables And Leachables: Risk Management And Analytical Solutions
10/11/2023
Partnering with a CDMO that offers comprehensive and robust E&L studies can help facilitate a smooth product launch by ensuring minimal impact from impurities, all while mitigating risks.
-
Taking Charge Of Your Stability Program
10/5/2022
Conducting stability studies is a critical aspect of the drug development process. Learn how consolidating stability testing with a single partner offers improved efficiency, reduced risk, and more.